Alpha memo: creatine does improve cognitive endpoint split

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Provide at least one peer-reviewed primary study or systematic review demonstrating cognitive improvement of creatine specifically in older adults, with endpoint, dose, and population details.
2. Clarify the actual bounded signal: is the claim (a) null in young, mixed/positive in older, or (b) endpoint-specific within a single population? The current memo asserts both ambiguously.
3. Rename the title to match what the receipts actually show, or expand the bundle so the title is defensible.
4. Remove the fabricated 'subgroup_endpoint_split geometry' label or define it with measurable criteria.

Major issues

• Title claims 'creatine does improve cognitive endpoint split' but the memo's own framing describes an unclear, gated signal (baseline-, subgroup-, or endpoint-gated) — no directional conclusion is supported.
• Receipt 2 is a Zenodo deposit (2026) whose excerpt is a hedged summary statement ('evidence suggests...further research needed'), not a primary RCT or meta-analysis; it cannot support a claim of cognitive improvement in older adults.
• Only two receipts anchor the entire memo: one is a null 2008 study in young adults (Rawson 2008), the other is an unverified Zenodo summary deposit; there is no actual evidence of a 'subgroup_endpoint_split' — the geometry label is asserted, not demonstrated.
• The one-sentence alpha is incoherent: it concatenates two paper titles into a pseudo-update ('made us expect... forces the update...') without articulating any mechanism, effect size, or bounded signal.
• The memos explicitly note 'further comprehensive research is needed' in Receipt 2, which by the review rubric should reject an accept verdict — but here the issue is worse: even the revise path is unsound because the source bundle does not support the stated claim.

Minor issues

• The 'Why this is surprising' section invents a 'subgroup_endpoint_split geometry' label with no operational definition.
• Falsifier list is generic and does not address the specific evidentiary weakness (Receipt 2 is not a primary cognitive RCT).
• Search receipt metadata (papers_searched=1456919317) appears corrupted/implausible as a count.

Reviewer note

Reject. The memo's title asserts a directional claim ('creatine does improve cognitive endpoint split') that the cited bundle does not support. Receipt 1 is a 2008 null study in young adults (Rawson, Physiol Behav) — useful as a contrast but not as positive evidence. Receipt 2 is a Zenodo 2026 deposit whose excerpt is a hedged, non-primary summary explicitly stating 'further comprehensive research is needed.' No primary RCT or meta-analysis in older adults is cited, no effect sizes or endpoints are reported, and the memos 'subgroup_endpoint_split geometry' is asserted without operationalization. The one-sentence alpha is syntactically garbled. This needs a scope reset: either restrict to a two-population contrast claim clearly bounded by the null young-adult study plus a real primary source for older adults, or retract the directional title.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis